Why Roivant Sciences Stock Bounced Back on Tuesday
Investors were in a forgiving mood after Monday's dispiriting earnings release.
Why Roivant Sciences Stock Was Slipping on Monday
The distinctive biotech wasn't a sector favorite as the trading week began.
Roivant Sciences Ltd. ( ROIV ) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +21.74% and -71.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Kura Oncology ( KURA ) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. ( RYTM ) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
What Does the Market Think About Roivant Sciences? - Roivant Sciences ( NASDAQ:ROIV )
Roivant Sciences's ROIV short percent of float has fallen 8.84% since its last report. The company recently reported that it has 41.10 million shares sold short, which is 8.25% of all regular shares that are available for trading.
Should Invesco S&P MidCap 400 GARP ETF ( GRPM ) Be on Your Investing Radar?
Style Box ETF report for ...
Is Invesco S&P MidCap 400 GARP ETF ( GRPM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Peering Into Roivant Sciences's Recent Short Interest - Roivant Sciences ( NASDAQ:ROIV )
Roivant Sciences's ROIV short percent of float has fallen 3.67% since its last report. The company recently reported that it has 44.43 million shares sold short, which is 8.92% of all regular shares that are available for trading.
Is Invesco S&P MidCap 400 Pure Growth ETF ( RFG ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC - Cardiff Oncology ( NASDAQ:CRDF )
- Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development - - Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m.
Roivant Sciences Ltd. ( ROIV ) Reports Q4 Loss, Lags Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -37.50% and 88.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ramaswami's Strive raises $750M for 'alpha-generating' Bitcoin buy strategy
Strive, an asset manager founded by American entrepreneur and politician Vivek Ramaswamy, has announced a $750 million raise to establish "alpha-generating" strategies through Bitcoin-related purchases. According to a May 27 announcement, the strategies will include buying undervalued biotech ...
Gossamer Bio ( GOSS ) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of 11.11% and 167.27%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Codexis ( CDXS ) Reports Q1 Loss, Misses Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -25% and 28.99%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B ( cHBV ) to date, including 2 patients who received no interferon ...
Spero Therapeutics, Inc. ( SPRO ) Reports Q1 Loss, Misses Revenue Estimates
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 54.55% and 46.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. ( LQDA ) Reports Q1 Loss, Misses Revenue Estimates
Liquidia Technologies (LQDA) delivered earnings and revenue surprises of -7.14% and 5.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strive to become Bitcoin treasury company
Strive Asset Management, founded by entrepreneur and former presidential candidate Vivek Ramaswamy, has revealed plans to transition into a Bitcoin treasury company.According to a May 7 announcement, Strive is going public through a reverse merger and plans to use the combined company's stock to ...
Should Invesco S&P MidCap 400 Pure Growth ETF ( RFG ) Be on Your Investing Radar?
Style Box ETF report for ...
Is Invesco S&P MidCap 400 Pure Growth ETF ( RFG ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Certara ( CERT ) Soars 8.0%: Is Further Upside Left in the Stock?
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024. outcome pending ...
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data - Immunovant ( NASDAQ:IMVT )
Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP but plans registrational studies for IMVT-1402 in both conditions.
Wall Street Analysts Believe Montes Archimedes Acquisition ( ROIV ) Could Rally 60%: Here's is How to Trade
The consensus price target hints at a 60% upside potential for Montes Archimedes Acquisition (ROIV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 ( GLOBE NEWSWIRE ) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ( LNP ) patent portfolio ( a subsidiary of Roivant Sciences, Ltd. ( ...
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Arbutus Biopharma ( NASDAQ:ABUS ) , Roivant Sciences ( NASDAQ:ROIV )
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 ( GLOBE NEWSWIRE ) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ( LNP ) patent portfolio ( a subsidiary of Roivant Sciences, Ltd.
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
In the dark days of the coronavirus pandemic, Moderna ( NASDAQ: MRNA ) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing ...
All You Need to Know About Montes Archimedes Acquisition ( ROIV ) Rating Upgrade to Buy
Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Roivant Sciences Tops Q3 Expectations
Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.
Roivant Sciences Ltd. ( ROIV ) Reports Q3 Loss, Tops Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 45.83% and 42.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Invesco S&P MidCap 400 Pure Growth ETF ( RFG ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Billionaire Vivek Ramaswamy To Run For Ohio Governor, Replacing DeWine: What Happens To Trump's DOGE Program?
'Vivek's base plan remains [the] same: to get accomplishments at DOGE and then announce a run for governor shortly,' says a source. Ramaswamy and Musk's goal is to cut $500 billion in annual spending from the federal government. Get the Real Story Behind Every Major Earnings Report
Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Roivant Sciences ( NASDAQ:ROIV )
Eric Venker, President & COO at Roivant Sciences ROIV, reported a large exercise of company stock options on January 1, according to a new SEC filing. What Happened: A Form 4 filing with the U.S.
Is Invesco S&P MidCap 400 GARP ETF ( GRPM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should Invesco S&P MidCap 400 GARP ETF ( GRPM ) Be on Your Investing Radar?
Style Box ETF report for ...
Roivant Sciences Ltd. ( ROIV ) Reports Q2 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -38.10% and 87.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Arbutus Biopharma ( NASDAQ:ABUS )
Cash runway into the fourth quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET
Is Invesco S&P MidCap 400 GARP ETF ( GRPM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should Invesco S&P MidCap 400 GARP ETF ( GRPM ) Be on Your Investing Radar?
Style Box ETF report for ...
At Roivant Sciences, Eric Venker Chooses To Exercise Options, Resulting In $782K - Roivant Sciences ( NASDAQ:ROIV )
A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences ROIV, reported the exercise of a large sell of company stock options. What Happened: A Form 4 filing from the U.S.
Options Exercise: Eric Venker At Roivant Sciences Realizes $782K - Roivant Sciences ( NASDAQ:ROIV )
A large exercise of company stock options by Eric Venker, President & COO at Roivant Sciences ROIV was disclosed in a new SEC filing on October 23, as part of an insider exercise. What Happened: A Form 4 filing from the U.S.
Price Over Earnings Overview: Roivant Sciences - Roivant Sciences ( NASDAQ:ROIV )
Looking into the current session, Roivant Sciences Inc. ROIV shares are trading at $11.88, after a 0.25% drop. Over the past month, the stock decreased by 0.63%, but over the past year, it actually went up by 38.39%.
Is First Trust Health Care AlphaDEX ETF ( FXH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should You Invest in the First Trust Health Care AlphaDEX ETF ( FXH ) ?
Sector ETF report for ...
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B - Organon ( NYSE:OGN ) , Roivant Sciences ( NASDAQ:ROIV )
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® ( tapinarof ) Cream, 1% - Organon ( NYSE:OGN ) , Roivant Sciences ( NASDAQ:ROIV )
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed acquisition extends Organon's international dermatology capabilities to the U.S.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® ( tapinarof ) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis ...
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer - Roivant Sciences ( NASDAQ:ROIV )
Tuesday, Roivant Sciences Ltd. ROIV created Pulmovant to in-license from Bayer AG BAYRY exclusive worldwide rights to develop and commercialize mosliciguat.
Does Montes Archimedes Acquisition ( ROIV ) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
